Q2 FY27 consolidated sales 26,585 lakh vs 14,359 lakh YoY; profit after tax 1,857 lakh vs 943 lakh
FREDUN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations was Rs 26,585.37 lakh versus Rs 14,358.53 lakh a year earlier, while profit after tax was Rs 1,857.42 lakh versus Rs 943.17 lakh. Revenue rose 85.2% and profit after tax rose 96.9%. The board approved the results and an NSE listing application. The auditor's review was unmodified.
Strong YoY sales and profit growth is positive for sentiment, and the proposed NSE listing may broaden investor access and trading liquidity.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.